Literature DB >> 18641990

Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival.

Kristen Foster1, Yong Wang, Daohong Zhou, Cynthia Wright.   

Abstract

PURPOSE: Malignant rhabdoid tumors (MRT), although rare, are one of the most aggressive pediatric malignancies. Loss of INI1, a tumor suppressor gene and member of the SWI/SNF chromatin remodeling complex, is a recurrent genetic characteristic of these tumors and an important diagnostic marker. We have previously demonstrated a novel interaction between the serine/threonine kinase Akt and INI1, as well as other SWI/SNF subunits. This, coupled with experiments in the literature suggesting that the PI3K/Akt pathway is dysregulated in MRT cells, caused us to investigate the activation and importance of this pathway in this tumor type.
METHODS: In this study, we used MTT assays to evaluate the sensitivity of MRT cell lines to PI3K inhibition. Western blot analysis and Raf pulldown assays were used to examine potential mechanisms of PI3K/Akt dysregulation.
RESULTS: Inhibition of the PI3K/Akt pathway caused a significant reduction in the survival of the four MRT cell lines tested, and three cell lines demonstrated constitutively active Akt. Two of these constitutively active Akt cell lines abundantly expressed IGF-1R and an inhibitor of IGF-1R, NVP-AEW541, reduced Akt phosphorylation in one of them. The third constitutively active Akt cell line appeared to express a mutant IGF-1R.
CONCLUSIONS: Our data suggests that the PI3K/Akt pathway is a crucial means of maintaining the survival and growth of MRT cells. The cells therefore employ various mechanisms to stimulate this pathway, and growth factor receptor dysregulation appears to be a common method. Drugs that inhibit the PI3K pathway or interfere with IGF autocrine loops may be of great value in treating MRT, which is largely resistant to conventional chemotherapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18641990      PMCID: PMC2692242          DOI: 10.1007/s00280-008-0796-5

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  60 in total

1.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Dissecting the regulatory circuitry of a eukaryotic genome.

Authors:  F C Holstege; E G Jennings; J J Wyrick; T I Lee; C J Hengartner; M R Green; T R Golub; E S Lander; R A Young
Journal:  Cell       Date:  1998-11-25       Impact factor: 41.582

3.  Transcriptional specificity of human SWI/SNF BRG1 and BRM chromatin remodeling complexes.

Authors:  Shilpa Kadam; Beverly M Emerson
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

4.  Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma.

Authors:  Mark G Slomiany; Leigh Ann Black; Megan M Kibbey; Melissa A Tingler; Terry A Day; Steven A Rosenzweig
Journal:  Cancer Lett       Date:  2006-09-22       Impact factor: 8.679

5.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Authors:  Incheol Shin; F Michael Yakes; Federico Rojo; Nah-Young Shin; Andrei V Bakin; Jose Baselga; Carlos L Arteaga
Journal:  Nat Med       Date:  2002-09-16       Impact factor: 53.440

6.  Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer.

Authors:  Ning Gao; Zhuo Zhang; Bing-Hua Jiang; Xianglin Shi
Journal:  Biochem Biophys Res Commun       Date:  2003-10-31       Impact factor: 3.575

7.  Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5.

Authors:  Zhi-Kai Zhang; Kelvin P Davies; Jeffrey Allen; Liang Zhu; Richard G Pestell; David Zagzag; Ganjam V Kalpana
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

8.  Loss of the INI1 tumor suppressor does not impair the expression of multiple BRG1-dependent genes or the assembly of SWI/SNF enzymes.

Authors:  Diem N Doan; Timothy M Veal; Zhijiang Yan; Weidong Wang; Stephen N Jones; Anthony N Imbalzano
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

9.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

View more
  12 in total

1.  Histone deacetylases expression in atypical teratoid rhabdoid tumors.

Authors:  Simone Treiger Sredni; Abby L Halpern; Christopher A Hamm; Maria de Fátima Bonaldo; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2012-11-10       Impact factor: 1.475

2.  A monoclonal antibody (Mc178-Ab) targeted to the ecto-ATP synthase β-subunit-induced cell apoptosis via a mechanism involving the MAPKase and Akt pathways.

Authors:  Wen-Juan Wang; Zhan Ma; Yi-Wen Liu; Yi-Qing He; Ying-Zhi Wang; Cui-Xia Yang; Yan Du; Mu-Qing Zhou; Feng Gao
Journal:  Clin Exp Med       Date:  2011-04-20       Impact factor: 3.984

3.  Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Authors:  Anjali Singh; Xueqing Lun; Aarthi Jayanthan; Halah Obaid; Yibing Ruan; Douglas Strother; Susan N Chi; Amy Smith; Peter Forsyth; Aru Narendran
Journal:  Mol Oncol       Date:  2013-01-11       Impact factor: 6.603

4.  Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.

Authors:  Samuel Wolf; Jana Lorenz; Joachim Mössner; Marcus Wiedmann
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

5.  A phase I trial of MK-2206 in children with refractory malignancies: a Children's Oncology Group study.

Authors:  Maryam Fouladi; John P Perentesis; Christine L Phillips; Sarah Leary; Joel M Reid; Renee M McGovern; Ashish M Ingle; Charlotte H Ahern; Matthew M Ames; Peter Houghton; L Austin Doyle; Brenda Weigel; Susan M Blaney
Journal:  Pediatr Blood Cancer       Date:  2014-03-24       Impact factor: 3.167

6.  Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation.

Authors:  Yibin Zhou; Peng Gu; Jian Li; Feng Li; Jin Zhu; Peng Gao; Yachen Zang; Yongchang Wang; Yuxi Shan; Dongrong Yang
Journal:  Oncol Rep       Date:  2017-09-18       Impact factor: 3.906

7.  Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.

Authors:  Ting Li; Jin Wang; Pengfei Liu; Jiadong Chi; Han Yan; Lei Lei; Zexing Li; Bing Yang; Xi Wang
Journal:  Oncotarget       Date:  2017-07-18

8.  Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.

Authors:  Yoshinori Imura; Hirohiko Yasui; Hidetatsu Outani; Toru Wakamatsu; Kenichiro Hamada; Takaaki Nakai; Shutaro Yamada; Akira Myoui; Nobuhito Araki; Takafumi Ueda; Kazuyuki Itoh; Hideki Yoshikawa; Norifumi Naka
Journal:  Mol Cancer       Date:  2014-08-07       Impact factor: 27.401

9.  Silibinin inhibits migration and invasion of the rhabdoid tumor G401 cell line via inactivation of the PI3K/Akt signaling pathway.

Authors:  Yumei Li; Chunmei Zhang; Danfeng Cai; Congde Chen; Dongmei Mu
Journal:  Oncol Lett       Date:  2017-10-20       Impact factor: 2.967

10.  SMARCC1 Suppresses Tumor Progression by Inhibiting the PI3K/AKT Signaling Pathway in Prostate Cancer.

Authors:  Zhao-Ming Xiao; Dao-Jun Lv; Yu-Zhong Yu; Chong Wang; Tao Xie; Tao Wang; Xian-Lu Song; Shan-Chao Zhao
Journal:  Front Cell Dev Biol       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.